Pharmacokinetics of Ranitidine in a Homogeneous Population of Intensive Care Unit Patients during Intermittent and Continuous Administration

References

• Weigelt J A. Current status of stress ulceration prophylaxis. Update in intensive care and emergency medicine, J L Vincent. Springer-Verlag, Berlin 1989; 361–7
   Google Scholar
• Shoemaker W C, Bland R D, Appel P L. Therapy of critically ill postoperative patients based on outcome prediction and prospective clinical trials. Surg Clin N Am 1985; 65: 811–33
   PubMedGoogle Scholar
• Skillmann J J, Gould S A, Chung R SK, Silen W. The gastric mucosal barrier: clinical and experimental studies in critically ill and normal man, and in the rabbit. Am Surg 1970; 172: 564–84
   Google Scholar
• Marrone G O, Silen W. Pathogenesis, diagnosis and treatment of acute mucosal lesions. Clin Gastroenterol 1984; 13: 635–50
   PubMedGoogle Scholar
• Idjadi F, Robbins R, Stahl W M, Essiet G. Prospective study of gastric secretion in stressed patients with intracranial injury. J Trauma 1971; 11: 681–6
   PubMedGoogle Scholar
• Fiddian-Green R G, McGough E, Pittenger G, Rothman E. Predictive value of intramural pH and other risk factors for massive bleeding from stress ulceration. Gastroenterology 1983; 85: 613–20
   PubMed Web of Science ®Google Scholar
• Geus W P, Lamers C BHW. Prevention of stress ulcer bleeding: a review. Scand J Gastroenterol 1990; 25: 32–41, Suppl 178
   Web of Science ®Google Scholar
• Zuckerman G R, Shuman R. Therapeutic goals and treatment options for prevention of stress ulcer syndrome. Am J Med 1987; 83: 29–35, Suppl 6A
   PubMedGoogle Scholar
• Hastings P R, Skillman J J, Bushnell L S, Silen W. Antacid titration in the prevention of acute gastrointestinal bleeding. N Engl J Med 1978; 298: 1041–5
   PubMed Web of Science ®Google Scholar
• Knight A, Bihari D, Tinker J. Stress ulceration in the critically ill patient. Br J Hosp Med 1985; 33: 216–9
   PubMedGoogle Scholar
• Shuman R B, Shuster D P, Zuckerman G R. Prophylactic ther-aphy for stress ulcer bleeding: a reappraisal. Ann Intern Med 1987; 106: 562–7
   PubMed Web of Science ®Google Scholar
• Lacroix J, Invante-Rivard C, Jenicek M, et al. Prophylaxis of upper gastrointestinal bleeding in in-tensive care units: a metaanalysis. Crit Care Med 1989; 17: 862–9
   PubMed Web of Science ®Google Scholar
• Ballesteros M A, Hogan D L, Koss M A, Isenberg J I. Bolus or intravenous infusion of ranitidine: effects on gastric pH and acid secretion. Ann Intern Med 1990; 112: 334–9
   PubMed Web of Science ®Google Scholar
• Rovers J P, Souney P F. A critical review of continuous infusion H2 receptor therapy. Crit Care Med 1989; 17: 814–21
   PubMed Web of Science ®Google Scholar
• Ketterl R, Hölscher A H, Weiser H F, Siewert J R. Kontrolle des intragastralen pH-Wertes bei sepsis bzw. peritonitis durch ranitidin versus cimetidin. Eine doppelblindstudie. Z Gastroenterol 1984; 22: 602–8
   PubMedGoogle Scholar
• Morris D L, Markham S, Beachey A, Byrne A. Bolus or infusion ranitidine for the control of intragastric pH in critically ill patients. Am J Gastroenterol 1985; 80: 865–6
   Google Scholar
• Santucci L, Fiorucci S, Pelli M A, et al. Control of gastric pH with ranitidine in critically ill patients. Comparison of two intravenous regimens. Dig Dig Sci 1991; 36: 583–7
   PubMedGoogle Scholar
• Lin J H. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. Clin Pharmaco-kinet 1991; 20: 218–36
   PubMed Web of Science ®Google Scholar
• Echizen H, Shoda R, Umeda N, Ishizaki T. Plasma famotidine concentration versus intragastric pH in patients with upper gastrointestinal bleeding and in healthy subjects. Clin Pharmacol Ther 1988; 44: 690–8
   PubMed Web of Science ®Google Scholar
• Roberts C JC. Clinical pharmacokinetics of ranitidine. Clin Phar-macokinet 1984; 9: 211–21
   PubMed Web of Science ®Google Scholar
• Ilett K F, Nation R L, Tjokrosetio R, et al. Pharmacokinetics of ranitidine in critically ill patients. Br J Clin Pharmacol 1986; 21: 279–88
   PubMedGoogle Scholar
• Milhaly G W, Drummer O H, Marshall A. High-pressure liquid chromatographic determination of ranitidine, a new H2-receptor antagonist, in plasma and urine. J Pharm Sci 1980; 69: 1155–7
   PubMedGoogle Scholar
• Proost J H, Meijer D KF. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992; 22: 155–63
   PubMed Web of Science ®Google Scholar
• Sewing K-F R. Pharmacodynamics and pharmacokinetics of ranitidine in man. The clinical use of ranitidine, J J Misiewitz, K G Wormsley. The Medicine Publishing Foundation, Oxford 1981; 32–40
   Google Scholar